Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors

Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors

SAN DIEGO, June 4, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company Kannalife, Inc. (“Kannalife”) (OTCQB: KLFE) has appointed biotechnology and pharmaceutical industry veteran Terrence O. Tormey to the company’s Board of Advisors.

“Kannalife continues to prove itself as a leader in cannabinoid research and its reputation to add well-respected biotech and pharmaceutical leaders like Terrence Tormey to its team amplifies its efforts,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

“It’s an honor to have Terry join our advisory board because his experience, vision and knowledge in the life sciences industry will help us start to design our commercialization and distribution plan for Atopidine™,” said Dean Petkanas, CEO of Kannalife.

Mr. Tormey brings over four decades of experience in the life sciences industry and has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson). Most recently he was the CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease.

“I am honored to serve as an advisor to Kannalife. The company has remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN) that, when approved, will help improve the lives of hundreds of thousands of patients,” Tormey said.

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.

The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

Investor Relations Contact:
P. (858) 283-4016
[email protected]

Cision

Cision

View original content: http://www.prnewswire.com/news-releases/medical-marijuana-inc-investment-company-kannalife-inc-appoints-terrence-o-tormey-to-board-of-advisors-301070501.html

SOURCE Medical Marijuana, Inc.

CBD Oil, 9 Most Well Guarded Secrets About Cannabinoid
Find out more